



Enalare Therapeutics to Present at BioNJ's Eleventh Annual BioPartnering Conference

PRINCETON, NJ, April 5, 2021 – Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, announced today that Herm Cukier, President and Chief Executive Officer, will be presenting at the BioNJ's Eleventh Annual BioPartnering Conference. The presentation will be recorded and visible for all registered participants of the conference which is scheduled virtually for May 18th and 19th. In addition, Mr. Cukier and Enalare's Chief Operating Officer, Daniel Motto, will host one-on-one investor and partnership meetings during the two-day event.

About Enalare Therapeutics Inc.

Enalare Therapeutics Inc. is a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, including respiratory depression caused by drug overdose, post-surgery, and other conditions. The Company is planning to initiate pivotal studies for its lead compound ENA-001 in the near term.

###

CONTACT:

Morgan Wagner

Investor Relations

mwagner@enalare.com